Jerrold Hill

1.3k total citations
36 papers, 950 citations indexed

About

Jerrold Hill is a scholar working on Economics and Econometrics, Geriatrics and Gerontology and Genetics. According to data from OpenAlex, Jerrold Hill has authored 36 papers receiving a total of 950 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 8 papers in Geriatrics and Gerontology and 6 papers in Genetics. Recurrent topics in Jerrold Hill's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Dementia and Cognitive Impairment Research (6 papers) and Pharmaceutical Economics and Policy (6 papers). Jerrold Hill is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Dementia and Cognitive Impairment Research (6 papers) and Pharmaceutical Economics and Policy (6 papers). Jerrold Hill collaborates with scholars based in United States, United Kingdom and Canada. Jerrold Hill's co-authors include Howard Fillit, Gregory P. Hess, Robert Futterman, Randall Brown, Dolores G. Clement, Sheldon M. Retchin, Simu K. Thomas, Eileen Fonseca, Curt D. Mueller and Peter J. Neumann and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Health Affairs.

In The Last Decade

Jerrold Hill

36 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jerrold Hill United States 19 351 270 209 118 105 36 950
Eleanor M. Perfetto United States 17 399 1.1× 278 1.0× 125 0.6× 190 1.6× 38 0.4× 81 1.3k
Tatiana Dilla Spain 20 246 0.7× 200 0.7× 170 0.8× 188 1.6× 106 1.0× 74 1.5k
Christopher Zacker United States 17 244 0.7× 202 0.7× 120 0.6× 97 0.8× 134 1.3× 49 1.2k
Maura McGuire United States 13 223 0.6× 451 1.7× 104 0.5× 247 2.1× 182 1.7× 44 1.5k
Emily R. Cox Australia 20 610 1.7× 183 0.7× 166 0.8× 89 0.8× 193 1.8× 56 1.5k
Zeba M. Khan United States 15 154 0.4× 114 0.4× 205 1.0× 42 0.4× 97 0.9× 49 897
Carolyn Harley United States 14 167 0.5× 92 0.3× 140 0.7× 126 1.1× 50 0.5× 33 980
Liz Payne United Kingdom 17 213 0.6× 155 0.6× 152 0.7× 110 0.9× 75 0.7× 27 1.4k
Nikki M. Carroll United States 24 225 0.6× 186 0.7× 170 0.8× 112 0.9× 275 2.6× 60 1.5k
Andrew M. Peterson United States 14 205 0.6× 118 0.4× 177 0.8× 163 1.4× 265 2.5× 55 1.3k

Countries citing papers authored by Jerrold Hill

Since Specialization
Citations

This map shows the geographic impact of Jerrold Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jerrold Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jerrold Hill more than expected).

Fields of papers citing papers by Jerrold Hill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jerrold Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jerrold Hill. The network helps show where Jerrold Hill may publish in the future.

Co-authorship network of co-authors of Jerrold Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Jerrold Hill. A scholar is included among the top collaborators of Jerrold Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jerrold Hill. Jerrold Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lyu, R., Qian Ding, Christopher M. Black, et al.. (2015). Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatology International. 36(1). 143–153. 23 indexed citations
2.
Coritsidis, George, Gregory A. Maglinte, Anjali Acharya, et al.. (2014). Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013. Clinical Therapeutics. 36(3). 408–418. 5 indexed citations
3.
McGuiness, Catherine B., et al.. (2013). The disease burden of pertussis in adults 50 years old and older in the United States: a retrospective study. BMC Infectious Diseases. 13(1). 32–32. 45 indexed citations
4.
Chen, Chi‐Chang, Gregory P. Hess, Zhimei Liu, et al.. (2012). Second-Line Treatment Outcomes After First-Line Sunitinib Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 10(4). 256–261. 18 indexed citations
5.
Hess, Gregory P., Arie Barlev, Karen Chung, Jerrold Hill, & Eileen Fonseca. (2012). Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiation Oncology. 7(1). 168–168. 27 indexed citations
6.
Hess, Gregory P., Jerrold Hill, Monika Raut, et al.. (2010). Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis. Advances in Therapy. 27(10). 743–755. 19 indexed citations
7.
Hess, Gregory P., et al.. (2010). Effect of reimbursement changes on erythropoiesis‐stimulating agent utilization and transfusions. American Journal of Hematology. 85(11). 838–843. 24 indexed citations
8.
Aronow, Herbert D., Gregory P. Hess, Jerrold Hill, Andreas Kuznik, & Larry Z. Liu. (2010). Switching From Atorvastatin to Simvastatin in Patients at High Cardiovascular Risk: Effects on Low-Density Lipoprotein Cholesterol. American Journal of Therapeutics. 17(2). 167–175. 25 indexed citations
9.
Polsky, Daniel, et al.. (2009). The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching. PharmacoEconomics. 27(9). 755–765. 10 indexed citations
10.
11.
Hess, Gregory P., Kafi N. Sanders, Jerrold Hill, & Larry Z. Liu. (2007). Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.. PubMed. 13 Suppl 3. S80–5. 23 indexed citations
12.
13.
Lu, Shaoli, Jerrold Hill, & Howard Fillit. (2005). Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: A case-control study. ˜The œAmerican journal of geriatric pharmacotherapy. 3(2). 92–102. 16 indexed citations
14.
Fillit, Howard & Jerrold Hill. (2004). The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias. Alzheimer Disease & Associated Disorders. 18. S24–S29. 17 indexed citations
15.
Fillit, Howard, Jerrold Hill, & Robert Futterman. (2003). Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.. PubMed. 34(7). 528–35. 80 indexed citations
16.
Neumann, Peter J., James K. Hammitt, Curt D. Mueller, et al.. (2001). Public Attitudes About Genetic Testing For Alzheimer’s Disease. Health Affairs. 20(5). 252–264. 90 indexed citations
17.
Ullman, Ralph, et al.. (1997). Satisfaction And Choice: A View From The Plans. Health Affairs. 16(3). 209–217. 31 indexed citations
18.
Brown, Randall, et al.. (1993). The Medicare Risk Program for HMOs: Final Summary Report on Findings from the Evaluation. Mathematica Policy Research Reports. 17 indexed citations
19.
Brown, Randall, et al.. (1993). Do health maintenance organizations work for Medicare?. PubMed. 15(1). 7–23. 110 indexed citations
20.
Phillips, Barbara, et al.. (1992). Case-Mix Analysis Using Demonstration Data: Home Health Prospective Payment Demonstration. Mathematica Policy Research Reports. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eleanor M. Perfetto Breakdown of academic impact, for papers by Tatiana Dilla Breakdown of academic impact, for papers by Christopher Zacker Breakdown of academic impact, for papers by Maura McGuire Breakdown of academic impact, for papers by Emily R. Cox Breakdown of academic impact, for papers by Zeba M. Khan Breakdown of academic impact, for papers by Carolyn Harley Breakdown of academic impact, for papers by Liz Payne Breakdown of academic impact, for papers by Nikki M. Carroll Breakdown of academic impact, for papers by Andrew M. Peterson
Rankless by CCL
2026